AGX-201 by AgoneX Biopharmaceuticals — Product Research | aVenture

AGX-201 is a subcutaneous injectable formulation of histamine dihydrochloride that AgoneX Biopharmaceuticals develops as a histamine receptor modulator, described as an H1 receptor antagonist and H3 receptor agonist acting on mast cells upstream of migraine initiation.

The candidate's Phase II trial, a multicenter study of subcutaneous AGX-201 for migraine prophylaxis, is registered as NCT02021474, and peer-reviewed 2024 coverage lists it among preventive migraine therapies alongside CGRP monoclonal antibodies. AgoneX reports three issued U.S. patents and one issued Japanese patent supporting the platform, with longer-term indications including Alzheimer's disease, Parkinson's disease, multiple sclerosis, chronic traumatic encephalopathy, and amyotrophic lateral sclerosis.

AGX-201 - Direct Competitors

Attribute	AGX-201	Ajovy	Emgality	Nurtec ODT	Qulipta	Vyepti
Provider	AgoneX Biopharmaceuticals agonexbio.com$36.9k disclosed funding · Pre-Seed	Teva Pharmaceutical Industries tevapharm.com$2.7B disclosed funding · Public	Eli Lilly and Company lilly.comPublic	Pfizer pfizer.com$31B disclosed funding · Public	AbbVie abbvie.com$250k disclosed funding · Public	Lundbeck lundbeck.comPublic
Founded	2011	1901	1876	1849	2013	1915
Sells To	Enterprise	Consumers, Enterprise	Consumers, Enterprise	Non-Profit	Enterprise	Enterprise
Pricing Model	Recurring, Software	Recurring, Software, Transactional	Recurring, Software, Transactional	Recurring	Recurring, Software	Recurring, Software
Ownership	Private	Public	Public	Private	Public	Public